Cronos Group (NASDAQ:CRON - Get Free Report) is anticipated to announce its Q4 2024 earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $48.64 million for the quarter. Investors that wish to listen to the company's conference call can do so using this link.
Cronos Group Trading Up 2.5 %
Shares of CRON stock traded up $0.05 during midday trading on Friday, reaching $2.05. 2,989,787 shares of the stock were exchanged, compared to its average volume of 1,730,258. Cronos Group has a 1 year low of $1.83 and a 1 year high of $3.14. The company's 50 day moving average is $1.97 and its two-hundred day moving average is $2.09. The firm has a market cap of $784.19 million, a PE ratio of -15.77, a price-to-earnings-growth ratio of 1.74 and a beta of 0.97.
About Cronos Group
(
Get Free Report)
Cronos Group Inc operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands.
Recommended Stories
Before you consider Cronos Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cronos Group wasn't on the list.
While Cronos Group currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
